Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 32.21 Million USD | -66.9% |
| 2022 | 97.32 Million USD | 156.07% |
| 2021 | 38 Million USD | -45.89% |
| 2020 | 70.23 Million USD | 74.14% |
| 2019 | 40.33 Million USD | 69.94% |
| 2018 | 23.73 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 41.63 Million USD | 15.86% |
| 2024 Q1 | 35.93 Million USD | 11.55% |
| 2023 Q2 | 104.05 Million USD | 4.11% |
| 2023 FY | 32.21 Million USD | -66.9% |
| 2023 Q4 | 32.21 Million USD | -53.86% |
| 2023 Q3 | 69.82 Million USD | -32.9% |
| 2023 Q1 | 99.94 Million USD | 2.69% |
| 2022 Q3 | 92.26 Million USD | 14.29% |
| 2022 Q2 | 80.72 Million USD | 30.14% |
| 2022 Q1 | 62.03 Million USD | 63.21% |
| 2022 FY | 97.32 Million USD | 156.07% |
| 2022 Q4 | 97.32 Million USD | 5.48% |
| 2021 Q2 | 92.98 Million USD | -4.31% |
| 2021 Q1 | 97.16 Million USD | 38.35% |
| 2021 FY | 38 Million USD | -45.89% |
| 2021 Q3 | 103.23 Million USD | 11.03% |
| 2021 Q4 | 38 Million USD | -63.19% |
| 2020 Q3 | 13.25 Million USD | 132.59% |
| 2020 Q4 | 70.23 Million USD | 429.79% |
| 2020 Q2 | -40.67 Million USD | -166.67% |
| 2020 Q1 | 61 Million USD | 51.26% |
| 2020 FY | 70.23 Million USD | 74.14% |
| 2019 FY | 40.33 Million USD | 69.94% |
| 2019 Q3 | 46.34 Million USD | 0.0% |
| 2019 Q1 | 69.2 Million USD | 204.41% |
| 2019 Q4 | 40.33 Million USD | -12.97% |
| 2018 FY | 23.73 Million USD | 0.0% |
| 2018 Q4 | 22.73 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -1673.835% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 944.43% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -2468.979% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 3530.777% |
| Better Therapeutics, Inc. | -860 Thousand USD | 3845.93% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 235.443% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -9708.459% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -604.923% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 653.237% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -907.348% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -917.311% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -544.042% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 75.966% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -17882.138% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -161.093% |
| Molecular Templates, Inc. | 707 Thousand USD | -4456.577% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -7247.575% |
| NexImmune, Inc. | -3.13 Million USD | 1128.037% |
| Orgenesis Inc. | 21.78 Million USD | -47.884% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -1131.46% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 6468975.502% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 783.877% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 25959.924% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 70.943% |
| Statera Biopharma, Inc. | 14.41 Million USD | -123.461% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 524.105% |
| Trevena, Inc. | 2.25 Million USD | -1326.705% |
| Vaxxinity, Inc. | 10.13 Million USD | -217.953% |
| Vaccinex, Inc. | -1.28 Million USD | 2601.165% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -9252.7% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -143.334% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -44666.682% |